Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility

References

• FieldsLEBurtVLCutlerJAHughesJRoccellaEJSorliePThe burden of adult hypertension in the United States 1999 to 2000: a rising tideHypertension200444439840415326093
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakAGuidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• CushmanWCThe burden of uncontrolled hypertension: morbidity and mortality associated with disease progressionJ Clin Hypertens (Greenwich)200353 Suppl 2142212826766
   PubMedGoogle Scholar
• PapademetriouVHypertension and cognitive function. Blood pressure regulation and cognitive function: a review of the literatureGeriatrics20056012022415700945
   PubMed Web of Science ®Google Scholar
• AlcocerLCuetoLHypertension, a health economics perspectiveTher Adv Cardiovasc Dis20082314715519124418
   PubMedGoogle Scholar
• OngKLCheungBMManYBLauCPLamKSPrevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004Hypertension2007491697517159087
   PubMed Web of Science ®Google Scholar
• AssmannGSchulteHThe Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart diseaseAm Heart J19881166 Pt 2171317243202078
   PubMed Web of Science ®Google Scholar
• WeiMMitchellBDHaffnerSMSternMPEffects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans. The San Antonio Heart StudyAm J Epidemiol199614411105810658942437
   PubMed Web of Science ®Google Scholar
• KannelWBRisk stratification in hypertension: new insights from the Framingham StudyAm J Hypertens2000131 Pt 23S10S10678282
   PubMed Web of Science ®Google Scholar
• ThomasFRudnichiABacriAMBeanKGuizeLBenetosACardiovascular mortality in hypertensive men according to presence of associated risk factorsHypertension20013751256126111358937
   PubMed Web of Science ®Google Scholar
• ManciaGParatiGBorghiCHypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH studyJ Hypertens200624583784316612244
   PubMed Web of Science ®Google Scholar
• AppelLJBrandsMWDanielsSRKaranjaNElmerPJSacksFMDietary approaches to prevent and treat hypertension: a scientific statement from the American Heart AssociationHypertension200647229630816434724
   PubMed Web of Science ®Google Scholar
• EnglertHSDiehlHAGreenlawRLWillichSNAldanaSThe effect of a community-based coronary risk reduction: the Rockford CHIPPrev Med200744651351917383717
   PubMed Web of Science ®Google Scholar
• BavikatiVVSperlingLSSalmonRDEffect of comprehensive therapeutic lifestyle changes on prehypertensionAm J Cardiol2008102121677168019064023
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• DahlöfBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• BakrisGLTotoRDMcCulloughPARochaRPurkayasthaDDavisPEffects of different ACE inhibitor combinations on albuminuria: results of the GUARD studyKidney Int200873111303130918354383
   PubMed Web of Science ®Google Scholar
• Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHgJAMA196720211102810344862069
   PubMed Web of Science ®Google Scholar
• Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm HgJAMA19702137114311524914579
   PubMed Web of Science ®Google Scholar
• Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative GroupJAMA19792422325622571490882
   PubMed Web of Science ®Google Scholar
• Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research GroupJAMA199126524325532642046107
   PubMed Web of Science ®Google Scholar
• StaessenJAFagardRThijsLRandomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial InvestigatorsLancet199735090807577649297994
   PubMed Web of Science ®Google Scholar
• BlackHRElliottWJGranditsGPrincipal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trialJAMA2003289162073208212709465
   PubMed Web of Science ®Google Scholar
• PepineCJHandbergEMCooper-DeHoffRMA calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trialJAMA2003290212805281614657064
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMLibbyPEffect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trialJAMA2004292182217222515536108
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• DuronERigaudASDubailDEffects of antihypertensive therapy on cognitive decline in Alzheimer’s diseaseAm J Hypertens20092291020102419590498
   PubMed Web of Science ®Google Scholar
• SkoogIAntihypertensive treatment and dementia preventionLancet Neurol20087866466518614403
   PubMed Web of Science ®Google Scholar
• PetersRBeckettNForetteFIncident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trialLancet Neurol20087868368918614402
   PubMed Web of Science ®Google Scholar
• AtlasSAThe renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibitionJ Manag Care Pharm2007138 Suppl S-bS9S2017605505
   PubMed Web of Science ®Google Scholar
• WeirMRProviding end-organ protection with renin-angiotensin system inhibition: the evidence so farJ Clin Hypertens (Greenwich)2006829910516470078
   PubMedGoogle Scholar
• MatcharDBMcCroryDCOrlandoLASystematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertensionAnn Intern Med20081481162917984484
   PubMed Web of Science ®Google Scholar
• MaggioniAPFabbriGVALIANT (VALsartan In Acute myocardial iNfarcTion) trialExpert Opin Pharmacother20056350751215794740
   PubMed Web of Science ®Google Scholar
• TurnbullFNealBPfefferMBlood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin systemJ Hypertens200725595195817414657
   PubMed Web of Science ®Google Scholar
• ReboldiGAngeliFCavalliniCGentileGManciaGVerdecchiaPComparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysisJ Hypertens20082671282128918550998
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• MannJFSchmiederREMcQueenMRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialLancet2008372963854755318707986
   PubMed Web of Science ®Google Scholar
• BrownMJCruickshankJKDominiczakAFBetter blood pressure control: how to combine drugsJ Hum Hypertens2003172818612574784
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• BenzJRBlackHRGraffAReedAFitzsimmonsSShiYValsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapyJ Hum Hypertens199812128618669883710
   PubMed Web of Science ®Google Scholar
• PoolJLGlazerRWeinbergerMAlvaradoRHuangJGraffAComparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adultsClin Ther2007291617317379047
   PubMed Web of Science ®Google Scholar
• JamersonKAZappeDHCollinsLDaleyWLThe time to blood pressure (BP) control by initiating antihypertensive therapy with a higher dose of valsartan (160 mg) or valsartan/hydrochlorothiazide compared to low-dose valsartan (80 mg) in the treatment of hypertension. The VELOCITY studyPresented at the 22nd Annual Scientific Meeting of the American Society of HypertensionMay 19–22, 2007Chicago IL, USA
   Google Scholar
• KollochREFerberPA randomized, double-blind study to compare a valsartan-based versus an amlodipine-based treatment algorithm in achieving blood pressure control: The PROMPT studyPresented at Hypertension 2008, the Joint Congress of the 18th Scientific Meeting of the European Society of Hypertension and the 22nd Scientific Meeting of the International Society of HypertensionJune 14–19, 2008Berlin, Germany
   Google Scholar
• LacourcièreYWrightJTJrSamuelRZappeDPurkayasthaDBlackHREffects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE studyBlood Press Monit200914311212019384192
   PubMed Web of Science ®Google Scholar
• MeierPMaillardMBurnierMThe future of angiotensin II inhibition in cardiovascular medicineCurr Drug Targets Cardiovasc Haematol Disord200551153015720221
   PubMedGoogle Scholar
• CalhounDAGlazerRDPettyjohnFSCoenenPDZhaoYGrossoAEfficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertensionCurr Med Res Opin20082482303231118593517
   PubMed Web of Science ®Google Scholar
• ZappeDHSowersJRHsuehWAMetabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndromeJ Clin Hypertens (Greenwich)2008101289490319120715
   PubMed Web of Science ®Google Scholar
• RaijLSowersJRJialalIMetabolic effects of combination angiotensin receptor blockade/hydrochlorothiazide in pre-diabetic, obese, hypertensive patientsPresented at the 18th Scientific Meeting of the European Society of Hypertension and the 22nd Scientific Meeting of the International Society of HypertensionJune 14–19, 2008Berlin, Germany
   Google Scholar
• WhiteWBCalhounDASamuelRTaylorAAZappeDHPurkayasthaDImproving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trialJ Clin Hypertens (Greenwich)200810645045818550935
   PubMed Web of Science ®Google Scholar
• MallionJMCarrettaRTrenkwalderPValsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapyBlood Press Suppl200312Suppl 1364312800986
   PubMedGoogle Scholar
• MalaccoESantonastasoMVariNAComparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) studyClin Ther200426685586515262456
   PubMed Web of Science ®Google Scholar
• FuenfstueckRHempelRDAnsariAWeidingerGKlebsSEfficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockersAdv Ther200522326327716236687
   PubMed Web of Science ®Google Scholar
• FogariRZoppiAMugelliniAHydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapyAdv Ther200623568069517142202
   PubMed Web of Science ®Google Scholar
• SchweizerJHilsmannUNeumannGHandrockRKlebsSEfficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combinationCurr Med Res Opin200723112877288517922981
   PubMed Web of Science ®Google Scholar
• EverettBMGlynnRJDanielsonERidkerPMCombination therapy versus monotherapy as initial treatment for stage 2 hypertension: A prespecified subgroup analysis of a community-based, randomized, open-label trialClin Ther200830466167218498915
   PubMed Web of Science ®Google Scholar
• WeirMRLevyDCrikelairNRochaRMengXGlazerRTime to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapyAm J Hypertens200720780781517586417
   PubMed Web of Science ®Google Scholar
• PhilippTSmithTRGlazerRTwo multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertensionClin Ther200729456358017617280
   PubMed Web of Science ®Google Scholar
• SmithTRPhilippTVaisseBAmlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studiesJ Clin Hypertens (Greenwich)20079535536417485971
   PubMedGoogle Scholar
• DestroMLuckowASamsonMKandraABrunelPEfficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS StudyJ Am Soc Hypertens20082429430220409909
   PubMed Web of Science ®Google Scholar
• PoldermansDGlazesRKargiannisSTolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertensionClin Ther200729227928917472820
   PubMed Web of Science ®Google Scholar
• FlackJMCalhounDASatlinLBarbierMHilkertRBrunelPEfficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND studyJ Hum Hypertens200923747948919190658
   PubMed Web of Science ®Google Scholar
• AllemannYFraileBLambertMBarbierMFerberPIzzoJLJrEfficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) studyJ Clin Hypertens (Greenwich)200810318519418326958
   PubMed Web of Science ®Google Scholar
• SinkiewiczWGlazerRDKavoliunieneAEfficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapyCurr Med Res Opin200925231532419192976
   PubMed Web of Science ®Google Scholar
• BrachmannJAnsariAMahlaGHandrockRKlebsSEffective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapyAdv Ther200825539941118465097
   PubMed Web of Science ®Google Scholar
• FogariRZoppiAMugelliniAEfficacy and safety of two treatment combinations of hypertension in very elderly patientsArch Gerontol Geriatr200948340140518457886
   PubMed Web of Science ®Google Scholar
• TrenkwalderPSchaetzlRBorbasEHandrockRKlebsSCombination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combinationBlood Press2008174132120973652
   PubMed Web of Science ®Google Scholar
• WeyckerDKeskinaslanALevyDGEdelsbergJKartashovAOsterGEffectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartanBlood Press200817Suppl 251220973651
   PubMed Web of Science ®Google Scholar
• BraunNUlmerHJAnsariAHandrockRKlebsSEfficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combinationCurr Med Res Opin200925242143019192987
   PubMed Web of Science ®Google Scholar
• PhilippTGlazerRDZhaoYPospiechRLong-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension studyCurr Med Res Opin200925118719319210151
   PubMed Web of Science ®Google Scholar
• MesserliFHVasodilatory edema: a common side effect of antihypertensive therapyAm J Hypertens2001149 Pt 197897911587169
   PubMed Web of Science ®Google Scholar
• SchraderJSalvettiACalvoCThe combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mgInt J Clin Pract200963221722519196360
   PubMed Web of Science ®Google Scholar
• BramleyTJGerbinoPPNightengaleBSFrech-TamasFRelationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizationsJ Manag Care Pharm200612323924516623608
   PubMed Web of Science ®Google Scholar
• JacksonKCIIShengXNelsonREKeskinaslanABrixnerDIAdherence with multiple-combination antihypertensive pharmacotherapies in a US managed care databaseClin Ther20083081558156318803997
   PubMed Web of Science ®Google Scholar
• BrixnerDIJacksonKCShengXNelsonREKeskinaslanAAssessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinationsCurr Med Res Opin20082492597260718812017
   PubMed Web of Science ®Google Scholar
• SaitoIKobayashiMMatsushitaYMoriAKawasugiKSarutaTCost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation modelHypertens Res20083171373138318957808
   PubMed Web of Science ®Google Scholar
• CorraoGZambonAParodiADiscontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in ItalyJ Hypertens200826481982418327094
   PubMed Web of Science ®Google Scholar
• WeberMAWengerNKDrug choice affects treatment compliance and blood pressure outcomes in elderly hypertensive patientsAm J Geriatr Cardiol200716527727817786055
   PubMedGoogle Scholar
• BorghiCVeronesiMDormiAPrandinMGCosentinoEStrocchiEPersistence of treatment and blood pressure control in elderly hypertensive patients treated with different classes of antihypertensive drugsAm J Geriatr Cardiol200716528028617786056
   PubMedGoogle Scholar
• KravitzRLMelnikowJMedical adherence research: time for a change in direction?Med Care200442319719915076818
   PubMed Web of Science ®Google Scholar
• LeeJKGraceKATaylorAJEffect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trialJAMA2006296212563257117101639
   PubMed Web of Science ®Google Scholar
• Krousel-WoodMHyreAMuntnerPMoriskyDMethods to improve medication adherence in patients with hypertension: current status and future directionsCurr Opin Cardiol200520429630015956826
   PubMed Web of Science ®Google Scholar
• FerriCCroceGDesideriGRole of combination therapy in the treatment of hypertension: Focus on valsartan plus amlodipineAdv Ther2008254299319
   Web of Science ®Google Scholar
• TaylorAACombination drug treatment of hypertension: have we come full circle?Curr Cardiol Rep20046642142615485601
   PubMedGoogle Scholar
• FaulknerMAHillemanDEAmlodipine/benazepril: fixed dose combination therapy for hypertensionExpert Opin Pharmacother20012116517811336577
   PubMedGoogle Scholar
• HessGHillJLauHDastaniHChaudhariPMedication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapyP&T2008331165266619750061
   PubMedGoogle Scholar
• GerbinoPPShoheiberOAdherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agentsAm J Health Syst Pharm200764121279128317563050
   PubMed Web of Science ®Google Scholar
• TaylorAAShoheiberOAdherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapyCongest Heart Fail20039632433214688505
   PubMedGoogle Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med2007120871371917679131
   PubMed Web of Science ®Google Scholar
• GadegbekuCALeaJPJamersonKAUpdate on disparities in the pathophysiology and management of hypertension: focus on African AmericansMed Clin North Am20058959213393016129104
   PubMed Web of Science ®Google Scholar
• ParkIUTaylorALRace and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic reviewAnn Fam Med20075544445217893387
   PubMed Web of Science ®Google Scholar
• DouglasJGBakrisGLEpsteinMManagement of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in BlacksArch Intern Med2003163552554112622600
   PubMedGoogle Scholar
• FlackJMEpidemiology and unmet need in hypertensionJ Manag Care Pharm2007138 Suppl S-bS2S8
   Web of Science ®Google Scholar
• GarberAJHandelsmanYEinhornDDiagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical EndocrinologistsEndocr Pract200814793394618996826
   PubMedGoogle Scholar
• AulakhGKSodhiRKSinghMAn update on non-peptide angiotensin receptor antagonists and related RAAS modulatorsLife Sci200781861563917692338
   PubMed Web of Science ®Google Scholar
• ElijovichFLafferCA role for single-pill triple therapy in hypertensionTher Adv Cardiovasc Dis20093323124019443512
   PubMedGoogle Scholar